NCT04932005 is a Phase 1 clinical trial of DZD2269 in Healthy Volunteers, sponsored by Dizal Pharmaceuticals.

Who is sponsoring NCT04932005?

NCT04932005 is sponsored by Dizal Pharmaceuticals.

What drugs are being tested in NCT04932005?

Interventions in NCT04932005: DZD2269, placebo.

What condition does NCT04932005 study?

NCT04932005 studies Healthy Volunteers.

Is NCT04932005 still recruiting?

NCT04932005 is currently completed. Last updated 1 July 2022.

Last reviewed 2022-07-01 · How we verify

NCT04932005

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of DZD2269 in Healthy Adult Participants

Completed Phase 1 Last updated 1 July 2022

What this trial tests

Phase 1 trial testing DZD2269 in Healthy Volunteers in 72 participants. Completed in 12 April 2022.

Timeline

29 June 2021

Primary endpoint
1 April 2022

12 April 2022

Quick facts

Lead sponsor	Dizal Pharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	72
Start date	29 June 2021
Primary completion	1 April 2022
Estimated completion	12 April 2022
Sites	1 location across United States

Drugs / interventions tested

DZD2269 — full drug profile →
placebo

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Dizal Pharmaceuticals — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a research study in healthy participants. The purpose of this study is to see how safe the study drug is and how well it is tolerated after dosing. This study will also investigate pharmacokinetics of DZD2269; renal excretion of DZD2269 will also be evaluated. The study will also measure biomarkers such as pCREB in the blood.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist.
Bai Y, Zhang X, Zheng J, Liu Z, et al · · 2022 · cited 21× · PMID 36229853 · DOI 10.1186/s13046-022-02511-1

Verify or expand the search:

Other trials of DZD2269

Trials testing the same drug.

NCT04634344 — Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC · Phase 1 · terminated

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Dizal Pharmaceuticals trials

Trials by the same sponsor.

NCT06813365 — Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2) · Phase 1 · recruiting
NCT07234162 — A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) · Phase 3 · recruiting
NCT06084104 — DZD9008 PK Study in Hepatic Impairment Subjects · Phase 1 · completed
NCT05926180 — Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and · Phase 1 · completed
NCT05824585 — DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04932005 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dizal Pharmaceuticals
Last refreshed: 1 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04932005.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing